Research programme: RHAMM peptides - Cangene

Drug Profile

Research programme: RHAMM peptides - Cangene

Alternative Names: RHAMM peptides research programme - Cangene

Latest Information Update: 21 Apr 2006

Price : $50

At a glance

  • Originator Cangene Corporation; The Hospital for Sick Children
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Burns; Wounds

Most Recent Events

  • 21 Apr 2006 No development reported - Preclinical for Wounds in Canada (unspecified route)
  • 21 Apr 2006 No development reported - Preclinical for Burns in Canada (unspecified route)
  • 26 Mar 2002 The RHAMM peptides research programme has been licensed to Transition Therapeutics in Canada.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top